{"id":752153,"date":"2023-04-27T10:55:24","date_gmt":"2023-04-27T14:55:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\/"},"modified":"2023-04-27T10:55:24","modified_gmt":"2023-04-27T14:55:24","slug":"zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\/","title":{"rendered":"ZyVersa Therapeutics&#8217; CEO, Stephen C. Glover, to Present at Sidoti Micro-Cap Virtual Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li>\n          <em>Mr. Glover to discuss key updates on the development status of ZyVersa\u2019s Phase 2a-ready Cholesterol Efflux Mediator\u2122 VAR 200 for renal disease and Inflammasome ASC Inhibitor IC 100 for numerous CNS and other inflammatory diseases<\/em>\n        <\/li>\n<\/ul>\n<p>WESTON, Fla., April  27, 2023  (GLOBE NEWSWIRE) &#8212; ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or \u201cZyVersa\u201d), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, will present at the Sidoti Micro-Cap Conference being held virtually May 10 \u2013 11, 2023.<\/p>\n<p>Details regarding ZyVersa\u2019s presentation are as follows:<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:20%;width:20%;min-width:20%\">\n            <strong>Event:<\/strong>\n          <\/td>\n<td style=\"max-width:80%;width:80%;min-width:80%\">\n            <strong>Sidoti Micro-Cap Virtual Conference<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Date:<\/strong>\n          <\/td>\n<td>\n            <strong>Wednesday, May 10, 2023<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Time:<\/strong>\n          <\/td>\n<td>\n            <strong>9:15 AM EDT<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Location:<\/strong>\n          <\/td>\n<td>\n            <strong><br \/>\n              <a href=\"https:\/\/investors.zyversa.com\/news-events\/events\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/investors.zyversa.com\/news-events\/events<\/a> (Day of Conference)<\/strong>\n          <\/td>\n<\/tr>\n<\/table>\n<p>\u201cWe are pleased to have the opportunity at the Sidoti Micro-Cap Virtual Conference to discuss ZyVersa\u2019s potential to build stockholder value as we advance development of our two platform technologies,\u201d stated Mr. Glover. \u201cZyVersa is currently advancing two product candidates, Phase 2a-ready Cholesterol Efflux Mediator<sup>TM<\/sup> VAR 200 designed to ameliorate renal lipid accumulation that damages the kidneys&#8217; filtration system, and Inflammasome ASC Inhibitor IC 100 in development to block initiation and perpetuation of damaging inflammation associated with numerous inflammatory diseases.\u201d<\/p>\n<p>To learn more about ZyVersa and its differentiated product pipeline, please schedule a one-on-one meeting with Mr. Glover through the conference portal.<\/p>\n<p>\n        <strong>About ZyVersa Therapeutics, Inc.<\/strong>\n      <\/p>\n<p>ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs for patients with renal and inflammatory diseases who have significant unmet medical needs. The Company is currently advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies \u2013 Cholesterol Efflux Mediator\u2122 VAR 200 developed to ameliorate renal lipid accumulation that damages the kidneys&#8217; filtration system in patients with glomerular kidney diseases, and Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation associated with numerous CNS and other inflammatory diseases. For more information, please visit www.zyversa.com.<\/p>\n<p>\n        <strong>Cautionary Statement Regarding Forward-Looking Statements <\/strong>\n      <\/p>\n<p>Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These include statements regarding management\u2019s intentions, plans, beliefs, expectations, or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. ZyVersa Therapeutics, Inc (\u201cZyVersa\u201d) uses words such as \u201canticipates,\u201d \u201cbelieves,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201cprojects,\u201d \u201cfuture,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cguidance,\u201d and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions. Such forward-looking statements are based on ZyVersa\u2019s expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including ZyVersa\u2019s plans to develop and commercialize its product candidates, the timing of initiation of ZyVersa\u2019s planned preclinical and clinical trials; the timing of the availability of data from ZyVersa\u2019s preclinical and clinical trials; the timing of any planned investigational new drug application or new drug application; ZyVersa\u2019s plans to research, develop, and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of ZyVersa\u2019s product candidates; ZyVersa\u2019s commercialization, marketing and manufacturing capabilities and strategy; ZyVersa\u2019s ability to protect its intellectual property position; and ZyVersa\u2019s estimates regarding future revenue, expenses, capital requirements and need for additional financing.<\/p>\n<p>New factors emerge from time-to-time, and it is not possible for ZyVersa to predict all such factors, nor can ZyVersa assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this press release are based on information available to ZyVersa as of the date of this press release. ZyVersa disclaims any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.<\/p>\n<p>This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities.<\/p>\n<p>\n        <strong>Corporate and IR Contact:<\/strong><br \/>\n        <br \/>Karen Cashmere<br \/>Chief Commercial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NdLlDB8nLQSTE_-hnUVnJyt6VaCw4sKUZWYn2SAPMKURRzYojlT5poWpGbLee7AAMSWvhHWtItcUYtWvr4vpfld8J36YnPlNsrY2yz654TA=\" rel=\"nofollow noopener\" target=\"_blank\">kcashmere@zyversa.com<\/a><br \/>786-251-9641\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n<p>\n        <strong>Media Contacts<\/strong><br \/>\n        <br \/>\n        <strong>Tiberend Strategic Advisors, Inc.<\/strong><br \/>\n        <br \/>Casey McDonald<br \/>cmcdonald@tiberend.com<br \/>646-577-8520<\/p>\n<p>Dave Schemelia<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eO6jlkwJLR_J15Ft0ltnPGdY2WTDtBePSM6xrtpgVBl2XnA-elHkLKXlQGk9is7mLPz4tqDP4THUx8NyrylzeNAcqljndEFS7H03206bVy4=\" rel=\"nofollow noopener\" target=\"_blank\">dschemelia@tiberend.com<\/a><br \/>609-468-9325<\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjYxNiM1NTYwMTM2IzIyNDQ1MTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MmMyZGZmZGItNDhmOC00NDdhLWJkZjgtNjUzYjAzZjdiM2Y5LTEyNTYwNjk=\/tiny\/ZyVersa-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Mr. Glover to discuss key updates on the development status of ZyVersa\u2019s Phase 2a-ready Cholesterol Efflux Mediator\u2122 VAR 200 for renal disease and Inflammasome ASC Inhibitor IC 100 for numerous CNS and other inflammatory diseases WESTON, Fla., April 27, 2023 (GLOBE NEWSWIRE) &#8212; ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or \u201cZyVersa\u201d), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, will present at the Sidoti Micro-Cap Conference being held virtually May 10 \u2013 11, 2023. Details regarding ZyVersa\u2019s presentation are as follows: Event: Sidoti Micro-Cap Virtual Conference Date: Wednesday, May 10, 2023 Time: 9:15 AM EDT &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ZyVersa Therapeutics&#8217; CEO, Stephen C. Glover, to Present at Sidoti Micro-Cap Virtual Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-752153","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ZyVersa Therapeutics&#039; CEO, Stephen C. Glover, to Present at Sidoti Micro-Cap Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ZyVersa Therapeutics&#039; CEO, Stephen C. Glover, to Present at Sidoti Micro-Cap Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Mr. Glover to discuss key updates on the development status of ZyVersa\u2019s Phase 2a-ready Cholesterol Efflux Mediator\u2122 VAR 200 for renal disease and Inflammasome ASC Inhibitor IC 100 for numerous CNS and other inflammatory diseases WESTON, Fla., April 27, 2023 (GLOBE NEWSWIRE) &#8212; ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or \u201cZyVersa\u201d), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, will present at the Sidoti Micro-Cap Conference being held virtually May 10 \u2013 11, 2023. Details regarding ZyVersa\u2019s presentation are as follows: Event: Sidoti Micro-Cap Virtual Conference Date: Wednesday, May 10, 2023 Time: 9:15 AM EDT &hellip; Continue reading &quot;ZyVersa Therapeutics&#8217; CEO, Stephen C. Glover, to Present at Sidoti Micro-Cap Virtual Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-27T14:55:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjYxNiM1NTYwMTM2IzIyNDQ1MTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ZyVersa Therapeutics&#8217; CEO, Stephen C. Glover, to Present at Sidoti Micro-Cap Virtual Conference\",\"datePublished\":\"2023-04-27T14:55:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\\\/\"},\"wordCount\":762,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjYxNiM1NTYwMTM2IzIyNDQ1MTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\\\/\",\"name\":\"ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Sidoti Micro-Cap Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjYxNiM1NTYwMTM2IzIyNDQ1MTY=\",\"datePublished\":\"2023-04-27T14:55:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjYxNiM1NTYwMTM2IzIyNDQ1MTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjYxNiM1NTYwMTM2IzIyNDQ1MTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ZyVersa Therapeutics&#8217; CEO, Stephen C. Glover, to Present at Sidoti Micro-Cap Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Sidoti Micro-Cap Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Sidoti Micro-Cap Virtual Conference - Market Newsdesk","og_description":"Mr. Glover to discuss key updates on the development status of ZyVersa\u2019s Phase 2a-ready Cholesterol Efflux Mediator\u2122 VAR 200 for renal disease and Inflammasome ASC Inhibitor IC 100 for numerous CNS and other inflammatory diseases WESTON, Fla., April 27, 2023 (GLOBE NEWSWIRE) &#8212; ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or \u201cZyVersa\u201d), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, will present at the Sidoti Micro-Cap Conference being held virtually May 10 \u2013 11, 2023. Details regarding ZyVersa\u2019s presentation are as follows: Event: Sidoti Micro-Cap Virtual Conference Date: Wednesday, May 10, 2023 Time: 9:15 AM EDT &hellip; Continue reading \"ZyVersa Therapeutics&#8217; CEO, Stephen C. Glover, to Present at Sidoti Micro-Cap Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-27T14:55:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjYxNiM1NTYwMTM2IzIyNDQ1MTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ZyVersa Therapeutics&#8217; CEO, Stephen C. Glover, to Present at Sidoti Micro-Cap Virtual Conference","datePublished":"2023-04-27T14:55:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\/"},"wordCount":762,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjYxNiM1NTYwMTM2IzIyNDQ1MTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\/","name":"ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Sidoti Micro-Cap Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjYxNiM1NTYwMTM2IzIyNDQ1MTY=","datePublished":"2023-04-27T14:55:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjYxNiM1NTYwMTM2IzIyNDQ1MTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjYxNiM1NTYwMTM2IzIyNDQ1MTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-present-at-sidoti-micro-cap-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ZyVersa Therapeutics&#8217; CEO, Stephen C. Glover, to Present at Sidoti Micro-Cap Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/752153","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=752153"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/752153\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=752153"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=752153"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=752153"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}